RedHill Biopharma in WHO Talks for Opaganib as Ebola Treatment Amid Outbreak
RDHL sits 35% above its 52-week low of $0.71.
Summary
RedHill Biopharma is in active discussions with the World Health Organization (WHO) and other partners to advance its investigational drug, opaganib, as a potential treatment for the ongoing Ebola outbreak, citing promising preclinical and clinical data.
Key Events · Product Development and Regulatory · RDHL
-
Opaganib for Ebola Discussions
RedHill Biopharma is actively discussing potential collaborations for the clinical advancement of its investigational drug, opaganib, as a treatment for Ebola Virus Disease (EVD), including with the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform.
-
Response to Ongoing Outbreak
These discussions are prompted by a rapidly evolving EVD outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are currently no approved medications or vaccines.
-
Supporting Clinical and Preclinical Data
The company highlights opaganib's Phase 3 clinical antiviral activity in severe COVID-19 (70.2% mortality reduction) and preclinical EVD activity, which showed inhibition of EVD in human macrophages, increased survival in one animal model, and synergistic effects with remdesivir.
-
Strategic Advantages
Opaganib is an orally administered, host-directed therapeutic (HDT) with a dual mechanism of action, offering ease of storage and distribution, which are critical logistical advantages for outbreak response.
Analysis · RDHL · Life Sciences
This news provides a significant positive development for RedHill Biopharma, which has recently faced a Nasdaq delisting notice and a going concern warning. Active discussions with the World Health Organization (WHO) for opaganib as a potential Ebola treatment, especially during an ongoing outbreak with no approved therapies for the specific sub-type, represent a material opportunity. While opaganib is still an investigational drug, the potential for a collaboration with a global health body like the WHO could provide crucial funding, validation, and a path to market, potentially alleviating some of the company's financial pressures and offering a new revenue stream. The drug's oral administration and ease of distribution are key advantages in outbreak scenarios.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDHL was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $0.71 to $3.31. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.